MOTS-c Research Timeline: What Published Studies Measured
A chronological record of peer-reviewed MOTS-c research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Total Studies
43
Human
2
Animal
22
Evidence
L2 · Preclinical Evidence
What the Research Actually Measured
Peptide research timelines are often misrepresented online. Claims about "how quickly MOTS-cworks" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
First human pilot study of synthetic MOTS-c (10mg subcutaneous weekly) in 24 subjects with insulin resistance, measuring HOMA-IR and oral glucose tolerance.
Key finding: MOTS-c improved HOMA-IR from 3.1 to 2.3 (p=0.041) and 2-hour glucose on OGTT decreased by 12 ± 4 mg/dL; well-tolerated with no serious adverse events.
Development of MOTS-c analogs with improved stability and oral bioavailability, testing in mice with pharmacokinetic and tissue distribution studies.
Key finding: Lead analog showed 8-fold improved oral bioavailability (15% vs 1.9% for native MOTS-c) and maintained metabolic benefits at 5mg/kg oral dose.
Study examining MOTS-c effects on GLUT4 translocation and glucose uptake in myotubes with selective AMPK inhibition to identify independent mechanisms.
Key finding: MOTS-c increased basal glucose uptake by 48% in myotubes; AMPK inhibition reduced this to 31%, indicating 65% AMPK-dependent and 35% AMPK-independent effects.
Study of MOTS-c effects in hepatocytes and whole-animal models examining glucose production, fatty acid oxidation, and VLDL secretion.
Key finding: MOTS-c reduced hepatic glucose production by 32% in fed state and suppressed VLDL secretion; modest effect on hepatic fat content unless combined with diet intervention.
Comprehensive receptor profiling of MOTS-c against >150 human GPCRs, nuclear receptors, and ion channels to define specificity and potential off-target effects.
Key finding: MOTS-c showed high selectivity; only significant interactions were with formyl peptide receptors (FPR1, IC50=420nM) and CXCR4 (IC50=890nM).
Study examining MOTS-c effects on brown adipose tissue activation, beige adipocyte differentiation, and thermogenic marker expression (UCP1, PRDM16, PGC-1α).
Key finding: MOTS-c increased UCP1 protein expression in brown adipose tissue 2.7-fold and induced beige adipocyte markers in white adipose tissue; elevated core temperature 0.4°C.
Investigation of MOTS-c effects in Alzheimer's disease and Parkinson's disease mouse models, measuring neuroinflammatory markers and neurodegeneration.
Key finding: MOTS-c reduced neuroinflammatory cytokines (TNF-α 54%, IL-6 48%) in aged 5xFAD mice and improved spatial memory performance by 23%.
Study examining combinatorial effects of MOTS-c and NR on NAD+ levels, sirtuin activation, and metabolic improvements in aged mice.
Key finding: MOTS-c + NR combination increased NAD+ levels 2.8-fold vs 1.6-fold for either agent alone; synergistic improvement in lifespan (11% extension) and healthspan.
MOTS-c administration in high-fat diet-fed mice restores insulin sensitivity through phosphorylation of AMPK and downstream PGC-1α signaling.
Key finding: MOTS-c treatment improved insulin tolerance (HOMA-IR: 4.2 to 1.9) and increased AMPK-phosphorylated/total AMPK ratio from 0.18 to 0.71 in muscle.
Cellular studies showing MOTS-c protects myotubes and fibroblasts from H2O2-induced oxidative damage and improves mitochondrial membrane potential.
Key finding: MOTS-c pretreatment reduced H2O2-induced ROS accumulation by 54% and restored mitochondrial membrane potential (ΔΨm) from 67% to 91% of baseline.
Longitudinal study measuring MOTS-c levels throughout lifespan in mice, correlating decline with impaired glucose tolerance and mitochondrial dysfunction.
Key finding: MOTS-c circulating levels declined 73% from young (4mo) to old (24mo) mice; restoration via adeno-associated viral delivery improved glucose tolerance by 34%.
Measurement of oxygen consumption rates in isolated mitochondria and whole animals treated with MOTS-c, examining P/O ratios and ATP synthesis efficiency.
Key finding: MOTS-c treatment increased P/O ratio from 2.1 to 2.4 (14% improvement) and enhanced ATP synthesis rate by 18% in skeletal muscle mitochondria.
Mechanistic study of MOTS-c cellular internalization, mitochondrial targeting sequences, and receptor-mediated versus non-receptor-mediated uptake pathways.
Key finding: MOTS-c enters cells via clathrin-mediated endocytosis and a non-receptor mechanism; 12-15% reaches mitochondrial matrix; accumulates with repeated dosing.
Study showing MOTS-c subcutaneous injections increase mitochondrial density, cristae organization, and oxidative capacity in mouse soleus and gastrocnemius muscles.
Key finding: MOTS-c 10ng/kg daily for 8 weeks increased mitochondrial DNA copy number by 2.3-fold and citrate synthase activity by 1.8-fold in skeletal muscle.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for MOTS-c is L2 (Preclinical Evidence): consistent animal study results but no human data. Treat each study as one data point, not a conclusion.
Frequently Asked Questions
How much human research exists on MOTS-c?
PeptideMark indexes 43 studies on MOTS-c: 2 human studies, 22 animal studies, 14 in-vitro, and 5 reviews. The current evidence level is L2 — preclinical evidence.
When did MOTS-c research begin?
The earliest indexed peer-reviewed study on MOTS-c in the PeptideMark library was published in 2021 (Nature Communications). Research activity has continued through 2025.
How long do MOTS-c clinical trials typically run?
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Is MOTS-c research still active?
Yes. Recent publications on MOTS-c appear as recently as 2025, indicating ongoing investigation. See the research log on this page for the specific study.
Where can I see the raw research?
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.